Edition:
India

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

96.83USD
19 Jan 2018
Change (% chg)

$6.36 (+7.03%)
Prev Close
$90.47
Open
$90.48
Day's High
$97.76
Day's Low
$90.48
Volume
171,817
Avg. Vol
169,243
52-wk High
$97.76
52-wk Low
$36.79

Chart for

About

Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.... (more)

Overall

Beta: --
Market Cap(Mil.): $2,616.89
Shares Outstanding(Mil.): 29.85
Dividend: --
Yield (%): --

Financials

BRIEF-Loxo Oncology Initiates Rolling Submission Of NDA To U.S. FDA For TRK Fusion Cancers Treatment

* LOXO ONCOLOGY INITIATES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR LAROTRECTINIB FOR THE TREATMENT OF TRK FUSION CANCERS

20 Dec 2017

BRIEF-Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability Of Response In TRK Fusion Cancers

* LOXO ONCOLOGY ANNOUNCES UPDATED LAROTRECTINIB PEDIATRIC CLINICAL TRIAL DATA DEMONSTRATING CONTINUED DURABILITY OF RESPONSE IN TRK FUSION CANCERS

04 Dec 2017

Loxo signs lucrative cancer drug deal with Bayer, but shares fall

Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.

14 Nov 2017

UPDATE 4-Loxo signs lucrative cancer drug deal with Bayer, but shares fall

Nov 14 Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.

14 Nov 2017

UPDATE 2-Loxo, Bayer to co-develop cancer drugs in up to $1.55 bln deal

Nov 14 Loxo Oncology will collaborate with Germany's Bayer to develop and commercialize two of its cancer therapies, the companies said, in a deal that could bring the U.S. drug developer up to $1.55 billion over the next few years.

14 Nov 2017

BRIEF-Bayer, Loxo Oncology form partnership to develop, commercialise cancer drugs​

* Says it and loxo oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer​

14 Nov 2017

BRIEF-Loxo Oncology announces development and commercialization partnership with Bayer for cancer drugs

* Loxo Oncology announces global development and commercialization partnership with Bayer for larotrectinib and LOXO-195

14 Nov 2017

Loxo Oncology to develop, commercialize cancer drugs with Bayer

Nov 14 U.S. drug developer Loxo Oncology Inc on Tuesday announced a deal with Bayer AG to develop and commercialize two of its cancer therapies and said it would receive $400 million upfront.

14 Nov 2017

BRIEF-Loxo Oncology reports quarterly loss per share of ‍$2.45

* Loxo Oncology announces third quarter 2017 financial results

02 Nov 2017

BRIEF-Loxo Oncology announces positive results from independent review committee assessment of larotrectinib dataset

* Loxo Oncology announces positive top-line results from independent review committee assessment of larotrectinib dataset

18 Oct 2017

Earnings vs. Estimates